WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY – Get Free Report) was the target of a large decline in short interest during the month of October. As of October 15th, there was short interest totaling 11,170 shares, a decline of 71.0% from the September 30th total of 38,536 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average trading volume of 63,773 shares, the days-to-cover ratio is currently 0.2 days.
Wall Street Analysts Forecast Growth
Separately, Zacks Research raised shares of WuXi Biologics (Cayman) to a “hold” rating in a research note on Friday, August 28th. One equities research analyst has rated the stock with a Hold rating. Based on data from MarketBeat.com, WuXi Biologics (Cayman) currently has a consensus rating of “Hold”.
Read Our Latest Report on WXXWY
WuXi Biologics (Cayman) Stock Down 1.7%
WuXi Biologics (Cayman) Company Profile
WuXi Biologics (Cayman) Inc is a global contract research, development and manufacturing organization (CRDMO) focused on biologic medicines. The company works with pharmaceutical and biotechnology companies to support the discovery, development and commercial manufacturing of therapies, helping customers advance drug candidates from early research through clinical and commercial production.
Its capabilities include antibody and recombinant protein development, cell-line development, process development, clinical trial material production and large-scale biomanufacturing.
See Also
- Five stocks we like better than WuXi Biologics (Cayman)
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Receive News & Ratings for WuXi Biologics (Cayman) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WuXi Biologics (Cayman) and related companies with MarketBeat.com's FREE daily email newsletter.
